Go to content
UR Home

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy

URN to cite this document:
urn:nbn:de:bvb:355-epub-514554
DOI to cite this document:
10.5283/epub.51455
Gerthofer, Valeria ; Scheiter, Alexander ; Lüke, Florian ; Keil, Felix ; Utpatel, Kirsten ; Pöhmerer, Laura-Maria-Giovanna ; Seitz, Johannes ; Niessen, Christoph ; Ignatov, Atanas ; Dietmaier, Wolfgang ; Calvisi, Diego F. ; Evert, Matthias ; Ortmann, Olaf ; Seitz, Stephan
Date of publication of this fulltext: 19 Jan 2022 16:00


Abstract

ALK fusions were first described by Morris et al1 in 1994. Several studies have reported genetic alterations of the ALK gene in various tumor types since then, consisting of mutations, amplifications, and fusions.1-3 Fusion proteins have an active C-terminal tyrosine kinase domain in common.3 Here, we describe an STRN-ALK fusion in malignant peritoneal mesothelioma (MPM), which has previously ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons